Nasdaq 100 Stocks SEC Filings — October 20, 2026

Revenue grew 22% YoY to $3.05B from $2.51B, worldwide procedures up ~15%, da Vinci placements rose to 546 from 427, FY2026 da Vinci procedure growth guided at 14%-15%

Non-GAAP net income rose to $1.05B ($3.00/share) from $867M ($2.40), though GAAP net income fell to $523M from $704M after the $450M antitrust charge, so the underlying earnings trajectory is strong while GAAP optics are weak

Q3 2026 operating margin expanded to 34.6% from 28.2% and diluted EPS rose to $0.87 from $0.59 on 12% revenue growth, showing strong operating leverage in the quarter

Q4 2026 operating margin guided down to 26.0% from Q3's 34.6% (and 24.5% prior year, including ~120 bps headcount impact), signaling a sequential margin reset that will pressure near-term EPS

2026 FCF guidance cut to ~$12.0B from $12.5B and ad revenue expectation trimmed to ~$2.7B from ~$3B, a double guidance reduction that weakens the monetization thesis

EMEA F/X-neutral growth decelerated to 9% from 15% YoY, and LATAM F/X-neutral growth fell to 12% from 20%, indicating regional momentum is slowing faster than reported 11% total growth suggests

President & CTO Scott Deboer sold 28,444 shares at $900 (~$25.6M) plus smaller tranches at $901-$902, retaining 147,430 shares; executed under a Rule 10b5-1 plan, so the sale is a scheduled diversification rather than a discretionary signal

EVP/CFO/COO Akash Palkhiwala sold ~940 shares at $175.89 across six transactions and retains 20,799 shares; 10b5-1 plan execution limits its information content, but the repeated sales are consistent with routine executive selling

Two DEFA14A filings reference an August 3, 2026 proxy and an October 16/20 communication date, suggesting active shareholder solicitation; without substantive content, no directional signal can be drawn

Q4 2026 operating margin guided to 26.0% vs Q3 actual 34.6%, an ~860 bps sequential step-down that the summary attributes only partly to headcount actions (~120 bps)

Ad revenue expectation cut ~10% (from ~$3B to ~$2.7B) for 2026, undermining a key growth lever for the ad-supported tier

EMEA F/X-neutral growth slowed 6 points YoY to 9% and LATAM slowed 8 points to 12%, with FX tailwinds masking the underlying decline

$450M antitrust class action settlement charge cut GAAP net income ~26% YoY and GAAP operating income ~22% YoY ($593M vs $760M), a material contingent-liability event

$22M net-of-tax IEEPA tariff refund benefited Q3 (~$0.06/share), so the period's clean earnings run-rate is lower than headline figures imply

FY2026 non-GAAP gross margin guidance of 68.7%-69.3% already embeds a 0.9% tariff impact, a persistent cost headwind on hardware-heavy revenue

Senior executive sold ~$25.6M at $900/share, a large single-day sale that could be read as a valuation-level sell signal despite the 10b5-1 framework

CFO/COO sold across six transactions at ~$172-$176, with cumulative disposals reducing direct holdings to 20,799 shares; repeated selling warrants monitoring for pattern shifts

Da Vinci placements up ~28% YoY (546 vs 427) feed a recurring procedure base; FY2026 procedure growth guided at 14%-15% with midpoint expectations, supporting a durable recurring-revenue thesis

Non-GAAP EPS of $3.00 vs $2.40 (+25% YoY) excluding one-time items indicates underlying earnings growth well ahead of GAAP, a potential re-rating catalyst once legal charges roll off

The Q4 margin reset to 26.0% includes ~120 bps of one-time headcount cost, so once restructuring benefits flow through, the company's structural margin profile (34.6% in Q3) offers recovery potential if the guidance proves conservative

Q3 revenue of $12.9B grew 12% reported and was in line with forecast, showing the top line is holding even as monetization assumptions are revised

Settling the $450M class action removes a discrete legal uncertainty, and the charge is now quantified, which can lower the risk premium for the stock

Insider transactions executed at ~$900/share indicate the stock has been trading at elevated levels, and the large pricing spread could support memory-cycle exposure for investors bullish on AI-driven DRAM/HBM demand

Insider sales clustered near $172-$176 across multiple transactions may mark a reference price range for investors evaluating entry into the name relative to recent trading levels

Netflix (+12% revenue, Q4 margin guided -850 bps sequentially) and Intuitive Surgical (+22% revenue, GAAP margins compressed YoY on legal charges) both show top-line strength coexisting with margin pressure, indicating operating-cost and one-time-item headwinds are outpacing revenue gains across large-cap NASDAQ-100 names [IMPLICATION: favor companies where margin pressure is one-time over structural]

Netflix lowered three guidance metrics (ad revenue, FCF, and 2026 revenue vs prior midpoint) in a single report, signaling that monetization assumptions in digital subscription and ad-supported models are being revised downward [IMPLICATION: scrutinize forward ad-revenue assumptions across streaming and digital-advertising peers]

Netflix's EMEA and LATAM F/X-neutral deceleration (to 9% and 12%) versus reported growth shows that international momentum is slowing and FX is masking it, a pattern likely relevant to other globally exposed NASDAQ-100 names [IMPLICATION: adjust for currency effects when comparing reported growth across multinationals]

Intuitive Surgical's $22M IEEPA tariff refund and its 0.9% guided tariff drag show trade policy is actively shaping reported earnings in both directions, requiring investors to normalize for policy-driven items [IMPLICATION: strip tariff refunds from earnings run-rates when valuing hardware and medtech exporters]

Micron and Qualcomm executives sold shares under Rule 10b5-1 plans at elevated prices, consistent with pre-scheduled diversification in semiconductor names; the signal value of such sales is low unless they break pattern or exceed plan size [IMPLICATION: track plan-adoption and modification disclosures for genuine conviction shifts]

The $450M antitrust settlement at Intuitive Surgical highlights litigation as a material earnings driver for dominant medtech platforms, a risk that may extend to other companies with concentrated market positions [IMPLICATION: include contingent-liability assessment in valuation of market-leading NASDAQ-100 platforms]

Watch whether operating margin lands near the 26.0% guide and whether ad revenue tracks toward the ~$2.7B reset; date not specified in the provided data

Monitor EMEA (9%) and LATAM (12%) F/X-neutral growth in the next report to see whether deceleration stabilizes or continues

Track da Vinci procedure growth against the 14%-15% range and non-GAAP gross margin against the 68.7%-69.3% band, with tariff impact (0.9%) as a key variable

Watch for final court approval, payment timing, and any further charges related to the $450M class action settlement

Monitor whether further sales by the President & CTO occur outside the existing 10b5-1 schedule or whether holdings change materially from 147,430 shares

Track subsequent Form 4 filings from the CFO/COO to see if selling continues and whether the position falls further from 20,799 shares

Watch for the substantive content and any vote outcome tied to the August 3, 2026 proxy, since the DEFA14A excerpts contain no operational detail